ADMA Biologics (NASDAQ:ADMA) Shares Cross Above 50 Day Moving Average – Should You Sell?

Shares of ADMA Biologics Inc (NASDAQ:ADMA) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $8.96 and traded as high as $9.04. ADMA Biologics shares last traded at $8.72, with a volume of 3,583,362 shares.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: ADMA faces mounting class-action and securities-fraud litigation, with multiple firms urging affected shareholders to pursue lead-plaintiff status before the August 10 deadline. Bragar Eagel & Squire class action announcement
• Negative Sentiment: Some legal notices allege possible misstatements about revenues and internal controls, which could increase uncertainty around ADMA Biologics’ reporting quality and future liability. Kessler Topaz investor alert
• Neutral Sentiment: Short interest data was updated, but the report showed zero shares outstanding, so it does not appear to provide a meaningful trading signal.

Analysts Set New Price Targets

ADMA has been the topic of a number of research analyst reports. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho dropped their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.67.

ADMA Biologics Trading Up 0.2%

The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $2.02 billion, a P/E ratio of 12.82 and a beta of 0.72. The business has a 50 day moving average of $8.96 and a 200-day moving average of $13.43.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. The firm had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business’s revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 earnings per share. Analysts anticipate that ADMA Biologics Inc will post 0.82 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, with a total value of $100,125.00. Following the purchase, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp lifted its holdings in shares of ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock valued at $248,014,000 after purchasing an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP grew its holdings in shares of ADMA Biologics by 27.0% during the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after buying an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after buying an additional 1,886,105 shares in the last quarter. Capital Research Global Investors raised its position in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares during the last quarter. Finally, Nuveen LLC raised its position in ADMA Biologics by 3.5% in the 4th quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock valued at $108,097,000 after buying an additional 202,245 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.